16-16 Segment 1: Direct to Consumer Drug Advertising

 

16-16a dtc

 

Synopsis: Since FDA rules on prescription drug advertising were loosened in 1997, the amount of advertising has mushroomed. However, there is still controversy over whether that’s good for patients, and now the American Medical Association has come out for an ad ban. Experts discuss the pro’s and cons of direct to consumer advertising and its effect on patients and physicians.

Stay in the loop! Follow us on Twitter and like us on Facebook!

Subscribe and review on iTunes!

Click here for guest information, audio and the transcript

Advertisements

16-07 Segment 1: Industry Funding of Clinical Trials

 

Synopsis: Clinical trials are much of the basis for the practice of medicine. Funding of trials has dramatically shifted so that today, trials paid for by pharmaceutical and device makers outnumber publically funded trials 6-to-1. Some studies indicate this makes bias in trials more likely, jeopardizing public health. Experts discuss.

Host: Reed Pence. Guests: Jocelyn Ullrich, Assistant Vice President of Science and Regulatory Advocacy, Pharmaceutical Research and Manufacturers of America (PhRMA); Dr. John Abramson, Lecturer in Healthcare Policy, Harvard Medical School; Dr. Joel Lexchin, emergency medicine physician and Professor of Health Policy, York University

Links for more information:

Stay in the loop! Follow us on Twitter and like us on Facebook!

Click here for the transcript